Expert Interviews

Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.

Dr Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DMO resolution.

Dr Lisa Nijm discusses how utilising a dexamethasone intracanalicular insert after cataract surgery saves time for practices.

Dr Firas Rahhal discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Dr Ted Leng discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

Dr Jill Hopkins discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular oedema.

At the 2021 American Academy of Ophthalmology annual meeting, Dr Penny Asbell discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

Dr Jay Duker discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

Dr Cathleen McCabe describes how VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Dr Timothy G. Murray discusses the 5-year followup data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.

Dr Nathan Steinle discusses top-line results of the OAKS and DERBY trials, testing the efficacy of pegcetacoplan for the treatment of geographic atrophy.

Dr Carl Regillo takes us through the history of the port delivery system, from ideation to US FDA approval.

Dr Victor Gonzalez discusses his presentation at ASRS, regarding 0.19mg fluocinolone acetonide implants in diabetic macular oedema (DMO) patients.

In his presentation at ASRS 2021, Dr Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular oedema in patients with retinal vein occlusion.

Dr W. Lloyd Clark discusses his presentation at ASRS 2021, "Impact of nonperfusion and leakage areas on diabetic macular oedema/vision-threatening complications in nonproliferative diabetic retinopathy (NPDR)."

Dr Leo Kim discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."

Dr Ankur Shah discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.

Dr Justis P. Ehlers discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021.

Prof Tunde Peto discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.

Dr Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.

Dr Grazia Pertile discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.

Dr Javier Zarranz-Ventura discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.

Dr Michael A. Singer speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Dr Mohamed Abou Shousha and Dr Richard Parrish II discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.